US 12,435,156 B2
Methods for treating neuroblastoma with combination therapy
Shakeel Modak, New York, NY (US)
Assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed by MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed on Feb. 22, 2021, as Appl. No. 17/181,321.
Application 17/181,321 is a continuation of application No. PCT/US2019/047657, filed on Aug. 22, 2019.
Claims priority of provisional application 62/721,433, filed on Aug. 22, 2018.
Prior Publication US 2021/0198379 A1, Jul. 1, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 31/437 (2006.01); A61K 31/53 (2006.01); A61K 38/19 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/3084 (2013.01) [A61K 31/437 (2013.01); A61K 31/53 (2013.01); A61K 38/193 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)] 15 Claims
 
1. A method of treating a human subject having chemoresistant neuroblastoma, comprising administering to the subject a therapeutically effective amount of an anti-GD2 antibody or an antigen-binding fragment thereof, and at least one hematopoietic growth factor, irinotecan, and temozolomide,
wherein the anti-GD2 antibody or antigen-binding fragment thereof each comprises:
a) a heavy chain variable region comprising a CDR1 comprising amino acid residues 31 to of SEQ ID NO: 4, a CDR2 comprising amino acid residues 50 to 65 of SEQ ID NO: 4, and a CDR3 comprising amino acid residues 98 to 108 of SEQ ID NO: 4, and a light chain variable region comprising a CDR1 comprising amino acid residues 24 to 34 of SEQ ID NO: 5, a CDR2 comprising amino acid residues 50 to 56 of SEQ ID NO: 5, and a CDR3 comprising amino acid residues 89 to 94 of SEQ ID NO: 5; or
b) a heavy chain variable region comprising a CDR1 comprising amino acid residues 31 to of SEQ ID NO: 11, a CDR2 comprising amino acid residues 50 to 65 of SEQ ID NO: 11, and a CDR3 comprising amino acid residues 98 to 108 of SEQ ID NO: 11, and a light chain variable region comprising a CDR1 comprising amino acid residues 24 to 34 of SEQ ID NO: 5, a CDR2 comprising amino acid residues 50 to 56 of SEQ ID NO: 5, and a CDR3 comprising amino acid residues 89 to 94 of SEQ ID NO: 5.